Intervention not reported
Progression free survival · Patients with brain metastases
The intervention showed no clear difference in progression free survival (low certainty).
1 finding from 1 review
Intervention not reported
Any intracranial disease progression at 1 year · Patients with brain metastases
The intervention may leads to lower any intracranial disease progression at 1 year (low certainty).
1 finding from 1 review
Intervention not reported
Neurocognitive function · Patients with brain metastases
1 finding from 1 review
Intervention not reported
Health related quality of life · Patients with brain metastases
1 finding from 1 review
Intervention not reported
Adverse events · Patients with brain metastases
1 finding from 1 review
Death from all causes · women with stage I endometrial cancer
Summary of findings: EBRT showed no clear difference in death from all causes compared with no EBRT (moderate certainty).
1 finding from 1 review
HR 0.99 [0.82, 1.2]
2628 participants
Moderate
Endometrial carcinoma‐related death · women with stage I endometrial cancer
Summary of findings: EBRT showed no clear difference in endometrial carcinoma‐related death compared with no EBRT (moderate certainty).
1 finding from 1 review
HR 0.96 [0.72, 1.28]
2965 participants
Moderate
Locoregional recurrence · women with stage I endometrial cancer
Summary of findings: EBRT leads to lower locoregional recurrence compared with no EBRT (high certainty).
1 finding from 1 review
HR 0.36 [0.25, 0.52]
2965 participants
High
Severe acute toxicity · women with stage I endometrial cancer
Summary of findings: EBRT leads to higher severe acute toxicity compared with no EBRT (high certainty).
1 finding from 1 review
RR 4.68 [1.35, 16.16]
1328 participants
High
Severe late toxicity · women with stage I endometrial cancer
Summary of findings: EBRT leads to higher severe late toxicity compared with no EBRT (high certainty).
1 finding from 1 review
RR 2.58 [1.61, 4.11]
3501 participants
High
Intervention not reported
Death within 5 years · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA)
The intervention showed no clear difference in death within 5 years (moderate certainty).
1 finding from 1 review
Intervention not reported
Disease progression within 5 years · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA)
The intervention probably leads to lower disease progression within 5 years (moderate certainty).
1 finding from 1 review
Intervention not reported
Haematological adverse events (grade 3 or 4) · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA)
The intervention showed no clear difference in haematological adverse events (grade 3 or 4) (moderate certainty).
1 finding from 1 review
Intervention not reported
Gastrointestinal adverse events (grade 3 or 4) · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA)
The intervention showed no clear difference in gastrointestinal adverse events (grade 3 or 4) (moderate certainty).
1 finding from 1 review
Intervention not reported
Genitourinary adverse events (grade 3 or 4) · patients with early‐stage cervical cancer (FIGO stages IB1, IB2 or IIA)
The intervention showed no clear difference in genitourinary adverse events (grade 3 or 4) (moderate certainty).
1 finding from 1 review